Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms

Secondary drug resistance stems from dynamic clonal evolution during the development of a prior primary resistance. This collateral type of resistance is often a characteristic of cancer recurrence. Yet, mechanisms that drive this collateral resistance and their drug-specific trajectories are still...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldonza, Mark Borris D., Ku, Jayoung, Hong, Ji-Young, Kim, Donghwa, Yu, Seung Jung, Lee, Min-Seok, Prayogo, Monica Celine, Tan, Stephanie, Kim, Dayeon, Han, Jinju, Lee, Sang Kook, Im, Sung Gap, Ryu, Han Suk, Kim, Yoosik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007258/
https://www.ncbi.nlm.nih.gov/pubmed/32083171
http://dx.doi.org/10.1126/sciadv.aav7416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007258/
https://www.ncbi.nlm.nih.gov/pubmed/32083171
http://dx.doi.org/10.1126/sciadv.aav7416

Ejemplares similares